

Performance in Initiating Clinical Trials Q3 2021-2022
First participant recruited

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Source of Delay	Comments
18/LO/0575	213457	A Validation Study of a computerized, Artificial Intelligence assisted cognitive assessment test compared to a widely used cognitive assessment test and specialist clinical diagnosis in patients with Alzheimer s Dementia and Mild Cognitive Impairment	06/01/2021	06/01/2021	16/05/2018	09/03/2021	09/03/2021	17/03/2021	05/05/2021	Sponsor	Contracting delays
20/NS/0029	277157	Real-world evidence study of primary care referrals to NHS memory clinics and the clinical and economic case for the adoption of the Integrated Cognitive Assessment to improve the dementia diagnosis pathway (ADePT)	23/04/2021	23/04/2021	27/02/2021	08/07/2021	07/07/2021	15/07/2021	13/09/2021		
21/WA/0151	287976	A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer s type, 20-AVP-786-306	04/01/2021	24/08/2021	17/08/2021	25/08/2021	24/09/2021	19/11/2021	N/A	NHS Provider	Site confirmed on 24.09.2021 (contract signed) but the study opening was delayed until 23.11.2021 due to key contact unavailability. Study has been awaiting 56 days to recruit the first participant considering the current opening date